Some results of the use of specific antiviral therapy in patients with a new coronavirus infection

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The study included 885 patients. According to the results on the second day of hospitalization, all patients were divided into two groups: patients with a negative PCR test result in the presence of clinical signs of coronavirus infection (group I, n=410) and patients with a positive PCR test result (group II, n=475). Initially, there were no differences between the groups in terms of severity, main clinical manifestations and the course of the disease at the time of hospitalization, during treatment, and at the time of discharge. The treatment success rate was 83.9%, relative to mortality – 96.6%. Based on the data received, there were no statistically significant differences in the results of treatment depending on the prescription of various types of specific antiviral therapy in patients with a new coronavirus infection regarding mortality and the development of complications.

About the authors

I. V. Gonchar

Branch No. 3 of the A.A.Vishnevsky 3rd Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation

Author for correspondence.
Email: nachmed-60@mail.ru

подполковник медицинской службы

Russian Federation, Odintsovo, Moscow Region

A. M. Kharisov

Branch No. 3 of the A.A.Vishnevsky 3rd Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation

Email: nachmed-60@mail.ru

кандидат медицинских наук, полковник медицинской службы

Russian Federation, Odintsovo, Moscow Region

A. L. Chernikov

Branch No. 3 of the A.A.Vishnevsky 3rd Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation

Email: nachmed-60@mail.ru

капитан

Russian Federation, Odintsovo, Moscow Region

A. V. Ershov

The V.A.Negovsky Research Institute of General Resuscitation of the Federal Scientific and Clinical Center for Resuscitation and Rehabilitation; The I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: salavatprof@mail.ru

доктор медицинских наук

Russian Federation, Moscow; Moscow

A. F. Sukhoterin

Health-resort «Zvenigorodsky» of the health-resort complex «Podmoskovye» of the Ministry of Defense of the Russian Federation

Email: salavatprof@mail.ru

кандидат медицинских наук, подполковник медицинской службы запаса

Russian Federation, Zvenigorod, Moscow region

References

  1. Воробьева Ю.Д., Дюкова Г.М. Астенический синдром в контексте пандемии COVID-19 // Мед. алфавит. – 2020. – № 33. – С. 26–34. DOI.org/10.33667/2078-5631-2020-33-26-34
  2. Громов А.А., Кручинина М.В., Рабко А.В. Коронавирусная болезнь COVID-19: неиспользованные возможности терапии // Рус. мед. журн. – 2020. – № 9. – С. 2–6.
  3. Зайцев А.А., Голухова Е.З., Мамалыга М.Л., Чернов С.А., Рыбка М.М., Крюков Е.В. и др. Эффективность пульс-терапии метилпреднизолоном у пациентов с COVID-19 // Клин. микробиология и антимикроб. химиотерапия. – 2020. – Т. 22, № 2. – С. 88–91.
  4. Зайцев А.А., Чернов С.А., Стец В.В., Паценко М.Б., Кудряшов О.И., Чернецов В.А., Крюков Е.В. Алгоритмы ведения пациентов с новой коронавирусной инфекцией COVID-19 в стационаре. Метод. реком. // Consilium Medicum. – 2020. – Т. 22, № 11. – С. 91–97.
  5. Руженцова Т.А. Возможности этиотропной терапии коронавирусной инфекции, вызванной SARS-COV-2, у амбулаторных пациентов // Мед. оппонент. – 2020. – № 1 (9). – С. 48–58. DOI.org/10.21055/preprints-3111729
  6. Туличев А.А., Марасанов Б.О., Авилкин И.С. и др. Опыт применения ингибитора JAK-киназ в сочетании с низкими дозами преднизолона в лечении тяжелой коронавирусной инфекции // Мед. альманах. – 2021. – № 1 (66). – С. 52–56.
  7. Чикина С.Ю., Бровко М.Ю., Роюк В.В., Авдеев С.Н. Нетипичное течение новой коронавирусной инфекции COVID-19 с поздним повышением уровня С-реактивного белка (клинические наблюдения) // Пульмонология. – 2020. – Т. 30, № 5. – С. 709–714. DOI.org/10.18093/0869-0189-2020-30-5-709-714
  8. Esakandari H., Nabi-Afjadi M., Fakkari-Afjadi J. et al. A comprehensive review of COVID-19 characteristics // Biol. Proced. Online. – 2020. – Vol. 22, N 19. doi: 10.1186/s12575-020- 00128-2
  9. Goldman J. D., Lye D. C.B., Hui D. S. et al. GS–US–540-5773 Investigators. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 // N. Engl. J. med. –2020. – Vol. 383, N 19. – Р. 1827–1837. DOI.org/10.1056/NEJMoa2015301
  10. Hossen M.S., Barek M.A., Jahan N. et al. A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges // SN Compr. Clin. Med. – 2020. – Р. 1–13. doi: 10.1007/s42399-020-00485-9
  11. Lopez-Jimenez F., Rohde L.E., Luna-Jimenez M.A. Problems and solutions in the interpretation of diagnostic tests // Rev. Invest. Clin. – 1998. – Vol. 50, N 1. – P. 65–72. PMID: 9608793
  12. Prakash A., Singh H., Kaur H. et al. Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients // Indian J. Pharmacol. – 2020. – Vol. 52, Iss. 5. – Р. 414–421. doi: 10.4103/ijp.ijp_998_20
  13. Udwadia Z.F., Singh P., Barkate H. et al. Efficacy and safety of favipiravir, an oral RNA–dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open–label, multicenter, phase 3 clinical trial // Int. J. Infect. Dis. – 2021. – N 103. – Р. 62–71. doi: 10.1016/j.ijid.2020.11.142
  14. Vabret N., Britton G. J., Gruber C. et al. Immunology of COVID-19: Current State of the Science // Immunity. – 2020. – Vol. 52, Iss. 6. – Р. 910–941. DOI.org/10.1016/j.immuni. 2020.05.002
  15. Wu L., O’Kane A.M., Peng H. et al. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management // Biochem. Pharmacol. – 2020. – Vol. 178. – Р. 114. DOI: 1 0.1016/j.bcp.2020.114114
  16. Yoshimoto F.K. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2 or n-COV19), the Cause of COVID-19 // Protein J. – 2020. – Vol. 39, Iss 3. – Р. 198–216. doi: 10.1007/s10930-020-09901-4

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Gonchar I.V., Kharisov A.M., Chernikov A.L., Ershov A.V., Sukhoterin A.F.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 01975 от 30.12.1992.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies